{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T03:21:52Z","timestamp":1787714512729,"version":"build-2784847793"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":71,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08469-4","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T08:14:38Z","timestamp":1781597678000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A novel therapeutic monoclonal antibody targeting PZR demonstrates potent anti-metastatic efficacy in triple-negative breast cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Jiayu","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayi","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingxiao","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuya","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqian","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhujun","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Licai","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haihua","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6162-500X","authenticated-orcid":false,"given":"Guang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"issue":"1","key":"8469_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clinicians. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clinicians"},{"key":"8469_CR2","first-page":"688","volume-title":"The natural history of hormone receptor-positive breast cancer","author":"E Lim","year":"2012","unstructured":"Lim E, Metzger-Filho O, Winer EP. The natural history of hormone receptor-positive breast cancer. Vol. 26. Oncology (Williston Park); 2012. p. 688\u201394, 96."},{"issue":"5","key":"8469_CR3","doi-asserted-by":"publisher","first-page":"544","DOI":"10.5858\/2010-0734-RAIR.1","volume":"135","author":"AM Gruver","year":"2011","unstructured":"Gruver AM, Portier BP, Tubbs RR. Molecular pathology of breast cancer: the journey from traditional practice toward embracing the complexity of a molecular classification. Arch Pathol Lab Med. 2011;135(5):544\u201357. https:\/\/doi.org\/10.5858\/2010-0734-RAIR.1.","journal-title":"Arch Pathol Lab Med"},{"issue":"6797","key":"8469_CR4","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1038\/35021093","volume":"406","author":"CM Perou","year":"2000","unstructured":"Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000;406(6797):747\u201352. https:\/\/doi.org\/10.1038\/35021093.","journal-title":"Nature"},{"issue":"21","key":"8469_CR5","doi-asserted-by":"publisher","first-page":"2492","DOI":"10.1001\/jama.295.21.2492","volume":"295","author":"LA Carey","year":"2006","unstructured":"Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the carolina breast cancer study. JAMA. 2006;295(21):2492\u2013502. https:\/\/doi.org\/10.1001\/jama.295.21.2492.","journal-title":"JAMA"},{"issue":"15","key":"8469_CR6","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15):4429\u201334. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-3045.","journal-title":"Clin Cancer Res"},{"issue":"7","key":"8469_CR7","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1007\/s10585-012-9496-y","volume":"29","author":"AT Stopeck","year":"2012","unstructured":"Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, et al. The role of targeted therapy and biomarkers in breast cancer treatment. Clin Exp Metastasis. 2012;29(7):807\u201319. https:\/\/doi.org\/10.1007\/s10585-012-9496-y.","journal-title":"Clin Exp Metastasis"},{"issue":"12","key":"8469_CR8","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.steroids.2012.07.019","volume":"77","author":"JM Renoir","year":"2012","unstructured":"Renoir JM. Estradiol receptors in breast cancer cells: associated co-factors as targets for new therapeutic approaches. Steroids. 2012;77(12):1249\u201361. https:\/\/doi.org\/10.1016\/j.steroids.2012.07.019.","journal-title":"Steroids"},{"issue":"2","key":"8469_CR9","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1007\/s11864-012-0186-4","volume":"13","author":"D Jelovac","year":"2012","unstructured":"Jelovac D, Wolff AC. The adjuvant treatment of HER2-positive breast cancer. Curr. Treat. Options Oncol. 2012;13(2):230\u201339. https:\/\/doi.org\/10.1007\/s11864-012-0186-4.","journal-title":"Curr. Treat. Options Oncol"},{"issue":"11","key":"8469_CR10","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1002\/ijc.27632","volume":"131","author":"MJ Duffy","year":"2012","unstructured":"Duffy MJ, McGowan PM, Crown J. Targeted therapy for triple-negative breast cancer: where are we? Intl J Cancer. 2012;131(11):2471\u201377. https:\/\/doi.org\/10.1002\/ijc.27632.","journal-title":"Intl J Cancer"},{"issue":"8","key":"8469_CR11","doi-asserted-by":"publisher","first-page":"5453","DOI":"10.1074\/jbc.275.8.5453","volume":"275","author":"R Zhao","year":"2000","unstructured":"Zhao R, Zhao ZJ. Dissecting the interaction of SHP-2 with PZR, an immunoglobulin family protein containing immunoreceptor tyrosine-based inhibitory motifs. J Biol Chem. 2000;275(8):5453\u201359. https:\/\/doi.org\/10.1074\/jbc.275.8.5453.","journal-title":"J Biol Chem"},{"issue":"45","key":"8469_CR12","doi-asserted-by":"publisher","first-page":"29367","DOI":"10.1074\/jbc.273.45.29367","volume":"273","author":"ZJ Zhao","year":"1998","unstructured":"Zhao ZJ, Zhao R. Purification and cloning of PZR, a binding protein and putative physiological substrate of tyrosine phosphatase SHP-2. J Biol Chem. 1998;273(45):29367\u201372. https:\/\/doi.org\/10.1074\/jbc.273.45.29367.","journal-title":"J Biol Chem"},{"issue":"8","key":"8469_CR13","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1038\/sj.mp.4001841","volume":"11","author":"G He","year":"2006","unstructured":"He G, Liu X, Qin W, Chen Q, Wang X, Yang Y, et al. MPZL1\/PZR, a novel candidate predisposing schizophrenia in han Chinese. Mol. Psychiatry. 2006;11(8):748\u201351. https:\/\/doi.org\/10.1038\/sj.mp.4001841.","journal-title":"Mol. Psychiatry"},{"issue":"15","key":"8469_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1172\/jci.insight.137753","volume":"5","author":"JS Yi","year":"2020","unstructured":"Yi JS, Perla S, Enyenihi L, Bennett AM. Tyrosyl phosphorylation of PZR promotes hypertrophic cardiomyopathy in PTPN11-associated Noonan syndrome with multiple lentigines. JCI Insight. 2020;5(15):5. https:\/\/doi.org\/10.1172\/jci.insight.137753.","journal-title":"JCI Insight"},{"issue":"15","key":"8469_CR15","doi-asserted-by":"publisher","first-page":"2874","DOI":"10.1128\/MCB.00135-14","volume":"34","author":"J Paardekooper Overman","year":"2014","unstructured":"Paardekooper Overman J, Yi JS, Bonetti M, Soulsby M, Preisinger C, Stokes MP, et al. PZR coordinates Shp2 Noonan and LEOPARD syndrome signaling in zebrafish and mice. Mol Cell Biol. 2014;34(15):2874\u201389. https:\/\/doi.org\/10.1128\/MCB.00135-14.","journal-title":"Mol Cell Biol"},{"issue":"2","key":"8469_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/cr.2013.158","volume":"24","author":"D Jia","year":"2014","unstructured":"Jia D, Jing Y, Zhang Z, Liu L, Ding J, Zhao F, et al. Amplification of MPZL1\/PZR promotes tumor cell migration through src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res. 2014;24(2):204\u201317. https:\/\/doi.org\/10.1038\/cr.2013.158.","journal-title":"Cell Res"},{"key":"8469_CR17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.3892\/or.2019.7199","volume":"42","author":"D Chen","year":"2019","unstructured":"Chen D, Cao L, Wang X. MPZL1 promotes tumor cell proliferation and migration via activation of src kinase in ovarian cancer. Oncol Rep. 2019;42:679\u201387. https:\/\/doi.org\/10.3892\/or.2019.7199.","journal-title":"Oncol Rep"},{"issue":"4","key":"8469_CR18","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1093\/abbs\/gmz019","volume":"51","author":"D Tan","year":"2019","unstructured":"Tan D, Zhang W, Tao Y, Galiya Y, Wang M. PZR promotes metastasis of colorectal cancer through increasing FAK and src phosphorylation. ABBS. 2019;51(4):356\u201364. https:\/\/doi.org\/10.1093\/abbs\/gmz019.","journal-title":"ABBS"},{"issue":"4","key":"8469_CR19","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/nrc2622","volume":"9","author":"DX Nguyen","year":"2009","unstructured":"Nguyen DX, Bos PD, Massague J. Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 2009;9(4):274\u201384. https:\/\/doi.org\/10.1038\/nrc2622.","journal-title":"Nat Rev Cancer"},{"key":"8469_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2012\/676731","volume":"2012","author":"G Bendas","year":"2012","unstructured":"Bendas G, Borsig L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. Int J Cell Biol. 2012;2012:1\u201310. https:\/\/doi.org\/10.1155\/2012\/676731.","journal-title":"Int J Cell Biol"},{"issue":"12","key":"8469_CR21","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1038\/nrc3628","volume":"13","author":"N Reymond","year":"2013","unstructured":"Reymond N, d\u2019Agua BB, Ridley AJ. Crossing the endothelial barrier during metastasis. Nat Rev Cancer. 2013;13(12):858\u201370. https:\/\/doi.org\/10.1038\/nrc3628.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"8469_CR22","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1186\/s12967-023-04696-1","volume":"21","author":"L Sun","year":"2023","unstructured":"Sun L, Guo S, Xie Y, Yao Y. The characteristics and the multiple functions of integrin \u03b21 in human cancers. J Transl Med. 2023;21(1):787. https:\/\/doi.org\/10.1186\/s12967-023-04696-1.","journal-title":"J Transl Med"},{"issue":"13","key":"8469_CR23","doi-asserted-by":"publisher","first-page":"6161","DOI":"10.1073\/pnas.92.13.6161","volume":"92","author":"Z Zhang","year":"1995","unstructured":"Zhang Z, Vuori K, Reed JC, Ruoslahti E. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates bcl-2 expression. Proc Natl Acad Sci USA. 1995;92(13):6161\u201365. https:\/\/doi.org\/10.1073\/pnas.92.13.6161.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"8469_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.cji.0000192105.24583.83","volume":"29","author":"LM Weiner","year":"2006","unstructured":"Weiner LM. Fully human therapeutic monoclonal antibodies. J Educ Chang Immunother. 2006;29(1):1\u20139. https:\/\/doi.org\/10.1097\/01.cji.0000192105.24583.83.","journal-title":"J Educ Chang Immunother"},{"issue":"4","key":"8469_CR25","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s13238-010-0052-8","volume":"1","author":"Z An","year":"2010","unstructured":"An Z. Monoclonal antibodies \u2014 a proven and rapidly expanding therapeutic modality for human diseases. Protein Cell. 2010;1(4):319\u201330. https:\/\/doi.org\/10.1007\/s13238-010-0052-8.","journal-title":"Protein Cell"},{"issue":"49","key":"8469_CR26","doi-asserted-by":"publisher","first-page":"7196","DOI":"10.1038\/s41388-020-01494-7","volume":"39","author":"L Zhang","year":"2020","unstructured":"Zhang L, Qin Y, Wu G, Wang J, Cao J, Wang Y, et al. PRRG4 promotes breast cancer metastasis through the recruitment of NEDD4 and downregulation of Robo1. Oncogene. 2020;39(49):7196\u2013208. https:\/\/doi.org\/10.1038\/s41388-020-01494-7.","journal-title":"Oncogene"},{"issue":"1","key":"8469_CR27","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41419-025-07354-0","volume":"16","author":"J Cao","year":"2025","unstructured":"Cao J, Zhou T, Wu T, Lin R, Huang J, Shi D, et al. Targeting estrogen-regulated system xc\u2212 promotes ferroptosis and endocrine sensitivity of ER+ breast cancer. Cell Death Dis. 2025;16(1):30. https:\/\/doi.org\/10.1038\/s41419-025-07354-0.","journal-title":"Cell Death Dis"},{"issue":"1","key":"8469_CR28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s42003-025-07513-1","volume":"8","author":"J Cao","year":"2025","unstructured":"Cao J, Wu T, Zhou T, Jiang Z, Ren Y, Yu J, et al. USP35 promotes the growth of ER positive breast cancer by inhibiting ferroptosis via BRD4-SLC7A11 axis. Commun Biol. 2025;8(1):64. https:\/\/doi.org\/10.1038\/s42003-025-07513-1.","journal-title":"Commun Biol"},{"issue":"14","key":"8469_CR29","doi-asserted-by":"publisher","first-page":"3844","DOI":"10.1158\/0008-5472.CAN-13-2730","volume":"74","author":"S Kwon","year":"2014","unstructured":"Kwon S, Choi KC, Kim YE, Ha YW, Kim D, Park BK, et al. Monoclonal antibody targeting of the cell surface molecule TM4SF5 inhibits the growth of hepatocellular carcinoma. Cancer Res. 2014;74(14):3844\u201356. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-2730.","journal-title":"Cancer Res"},{"issue":"1","key":"8469_CR30","doi-asserted-by":"publisher","first-page":"78","DOI":"10.7150\/thno.21278","volume":"8","author":"G Wu","year":"2018","unstructured":"Wu G, Kim D, Kim JN, Park S, Maharjan S, Koh H, et al. A Mucin1 C-terminal subunit-directed monoclonal antibody targets overexpressed Mucin1 in breast cancer. Theranostics. 2018;8(1):78\u201391. https:\/\/doi.org\/10.7150\/thno.21278.","journal-title":"Theranostics"},{"issue":"48","key":"8469_CR31","doi-asserted-by":"publisher","first-page":"79170","DOI":"10.18632\/oncotarget.13005","volume":"7","author":"G Wu","year":"2016","unstructured":"Wu G, Kim D, Park BK, Park S, Ha JH, Kim TH, et al. Anti-metastatic effect of the TM4SF5-specific peptide vaccine and humanized monoclonal antibody on colon cancer in a mouse lung metastasis model. Oncotarget. 2016;7(48):79170\u201386. https:\/\/doi.org\/10.18632\/oncotarget.13005.","journal-title":"Oncotarget"},{"issue":"4","key":"8469_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3390\/antib8040055","volume":"8","author":"ML Chiu","year":"2019","unstructured":"Chiu ML, Goulet DR, Teplyakov A, Gilliland GL. Antibody structure and function: the basis for Engineering therapeutics. Antibodies (Basel). 2019;8(4):8. https:\/\/doi.org\/10.3390\/antib8040055.","journal-title":"Antibodies (Basel)"},{"issue":"8","key":"8469_CR33","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","volume":"24","author":"MA Harris","year":"2024","unstructured":"Harris MA, Savas P, Virassamy B, O\u2019Malley MMR, Kay J, Mueller SN, et al. Towards targeting the breast cancer immune microenvironment. Nat Rev Cancer. 2024;24(8):554\u201377. https:\/\/doi.org\/10.1038\/s41568-024-00714-6.","journal-title":"Nat Rev Cancer"},{"issue":"18","key":"8469_CR34","doi-asserted-by":"publisher","first-page":"4641","DOI":"10.1158\/0008-5472.CAN-21-1109","volume":"81","author":"LC Tsao","year":"2021","unstructured":"Tsao LC, Force J, Hartman ZC. Mechanisms of therapeutic antitumor monoclonal antibodies. Cancer Res. 2021;81(18):4641\u201351. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-1109.","journal-title":"Cancer Res"},{"issue":"9","key":"8469_CR35","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1158\/0008-5472.CAN-15-1325","volume":"76","author":"MB Chen","year":"2016","unstructured":"Chen MB, Lamar JM, Li R, Hynes RO, Kamm RD. Elucidation of the roles of tumor integrin \u03b21 in the extravasation stage of the metastasis cascade. Cancer Res. 2016;76(9):2513\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1325.","journal-title":"Cancer Res"},{"issue":"9","key":"8469_CR36","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J. Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer. 2018;18(9):533\u201348. https:\/\/doi.org\/10.1038\/s41568-018-0038-z.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"8469_CR37","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1158\/0008-5472.CAN-21-0622","volume":"82","author":"U Ray","year":"2022","unstructured":"Ray U, Jung DB, Jin L, Xiao Y, Dasari S, Sarkar Bhattacharya S, et al. Targeting LRRC15 inhibits metastatic dissemination of ovarian cancer. Cancer Res. 2022;82(6):1038\u201354. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-0622.","journal-title":"Cancer Res"},{"issue":"1","key":"8469_CR38","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1186\/1479-5876-11-307","volume":"11","author":"B Petricevic","year":"2013","unstructured":"Petricevic B, Laengle J, Singer J, Sachet M, Fazekas J, Steger G, et al. Trastuzumab mediates antibody-dependent cell-mediated cytotoxicity and phagocytosis to the same extent in both adjuvant and metastatic HER2\/neu breast cancer patients. J Transl Med. 2013;11(1):307. https:\/\/doi.org\/10.1186\/1479-5876-11-307.","journal-title":"J Transl Med"},{"issue":"23","key":"8469_CR39","doi-asserted-by":"publisher","first-page":"4694","DOI":"10.1182\/blood-2013-02-482570","volume":"121","author":"D Rudnicka","year":"2013","unstructured":"Rudnicka D, Oszmiana A, Finch DK, Strickland I, Schofield DJ, Lowe DC, et al. Rituximab causes a polarization of B cells that augments its therapeutic function in NK-cell\u2013mediated antibody-dependent cellular cytotoxicity. Blood. 2013;121(23):4694\u2013702. https:\/\/doi.org\/10.1182\/blood-2013-02-482570.","journal-title":"Blood"},{"issue":"1","key":"8469_CR40","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/imr.13379","volume":"328","author":"G Hale","year":"2024","unstructured":"Hale G. Living in LALA land? Forty years of attenuating Fc effector functions. Immunological Rev. 2024;328(1):422\u201337. https:\/\/doi.org\/10.1111\/imr.13379.","journal-title":"Immunological Rev"},{"issue":"5","key":"8469_CR41","first-page":"65","volume":"13","author":"L Vasileva","year":"1976","unstructured":"Vasileva L, Dumanova L. [Effects of concanavalin a on the adsorption and penetration of paramyxoviruses into cells]. Vet Med Nauki. 1976;13(5):65\u201369.","journal-title":"Vet Med Nauki"},{"key":"8469_CR42","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.jim.2017.03.021","volume":"446","author":"MK Verma","year":"2017","unstructured":"Verma MK, Clemens J, Burzenski L, Sampson SB, Brehm MA, Greiner DL, et al. A novel hemolytic complement-sufficient NSG mouse model supports studies of complement-mediated antitumor activity in vivo. J Immunol Methods. 2017;446:47\u201353. https:\/\/doi.org\/10.1016\/j.jim.2017.03.021.","journal-title":"J Immunol Methods"},{"issue":"11","key":"8469_CR43","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1517\/17460441.2010.514326","volume":"5","author":"A Nechansky","year":"2010","unstructured":"Nechansky A, Kircheis R. Immunogenicity of therapeutics: a matter of efficacy and safety. Expert Opin Drug Discov. 2010;5(11):1067\u201379. https:\/\/doi.org\/10.1517\/17460441.2010.514326.","journal-title":"Expert Opin Drug Discov"},{"issue":"3","key":"8469_CR44","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/pharmaceutics13030422","volume":"13","author":"Y Tang","year":"2021","unstructured":"Tang Y, Cao Y. Modeling pharmacokinetics and pharmacodynamics of therapeutic antibodies: progress, Challenges, and future directions. Pharmaceutics. 2021;13(3):13. https:\/\/doi.org\/10.3390\/pharmaceutics13030422.","journal-title":"Pharmaceutics"},{"issue":"23\u201324","key":"8469_CR45","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.drudis.2007.10.002","volume":"12","author":"BM Agoram","year":"2007","unstructured":"Agoram BM, Martin SW, van der Graaf PH. The role of mechanism-based pharmacokinetic\u2013pharmacodynamic (PK\u2013PD) modelling in translational research of biologics. Drug Discov. Today Today. 2007;12(23\u201324):1018\u201324. https:\/\/doi.org\/10.1016\/j.drudis.2007.10.002.","journal-title":"Drug Discov. Today Today"},{"issue":"10","key":"8469_CR46","doi-asserted-by":"publisher","first-page":"103964","DOI":"10.1016\/j.xphs.2025.103964","volume":"114","author":"HR Megathlin","year":"2025","unstructured":"Megathlin HR, Burzenski L, Brehm MA, Greiner DL, Balu-Iyer S, Shultz LD. Increased longevity of circulating human IgG in an NSG Fc gamma receptor-1 deficient humanized mouse model. J Pharm Sci. 2025;114(10):103964. https:\/\/doi.org\/10.1016\/j.xphs.2025.103964.","journal-title":"J Pharm Sci"},{"issue":"7","key":"8469_CR47","doi-asserted-by":"publisher","first-page":"1820","DOI":"10.1158\/0008-5472.CAN-17-1958","volume":"78","author":"SK Sharma","year":"2018","unstructured":"Sharma SK, Chow A, Monette S, Vivier D, Pourat J, Edwards KJ, et al. Fc-mediated anomalous Biodistribution of therapeutic antibodies in immunodeficient mouse models. Cancer Res. 2018;78(7):1820\u201332. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-1958.","journal-title":"Cancer Res"},{"issue":"7","key":"8469_CR48","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/s41577-022-00821-1","volume":"23","author":"M Pyzik","year":"2023","unstructured":"Pyzik M, Kozicky LK, Gandhi AK, Blumberg RS. The therapeutic age of the neonatal Fc receptor. Nat Rev Immunol. 2023;23(7):415\u201332. https:\/\/doi.org\/10.1038\/s41577-022-00821-1.","journal-title":"Nat Rev Immunol"},{"issue":"2","key":"8469_CR49","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40259-021-00471-0","volume":"35","author":"S Ko","year":"2021","unstructured":"Ko S, Jo M, Jung ST. Recent achievements and Challenges in prolonging the serum half-lives of therapeutic IgG antibodies through Fc Engineering. BioDrugs. 2021;35(2):147\u201357. https:\/\/doi.org\/10.1007\/s40259-021-00471-0.","journal-title":"BioDrugs"},{"key":"8469_CR50","doi-asserted-by":"publisher","unstructured":"Nguyen J, Lafitte M, Barbery M, Espie K, Jeitany M, Larive R, et al. Progastrin promotes colorectal cancer stem cell-like properties via the receptor PZR. Adv Sci. 2025;12(38):e02136. https:\/\/doi.org\/10.1002\/advs.202502136.","DOI":"10.1002\/advs.202502136"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08469-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08469-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08469-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T02:30:20Z","timestamp":1787711420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08469-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8469"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08469-4","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The animal experiments were performed in accordance with the guidelines of the Animal Care and Use Committee at the Wenzhou Medical University (Permit no. wydw2025-0105).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have agreed to publish this manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1094"}}